CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development.
Thomas Cornell, Senior Manager of Protein Engineering at Abzena joins the podcast to talk about the world of protein engineering, how it’s an invaluable tool for improving the stability, functionality, and applicability for drug products.
Cornell gained his PhD from Kings College London in the field of Chemical Biology. He then moved into the biotech startup space and spent almost a decade in preclinical vaccine research and development, focused on subunit vaccines. After working on over 20 protein families, Cornell has gained a wealth of protein engineering experience. Joining Abzena 2 years ago and now working within the protein engineering department on pre-clinical development of antibody drug candidates places Cornell at the heart of drug development at Abzena.
The podcast covers the field of protein engineering more broadly, and includes the parts that are particularly exciting at the minute. We explore more in depth the key aspects of antibody drugs, how these can improve patient outcomes by being more specfic and stable, and the potential for bispecifics in improving functionality. We also touched on the wider considerations of the field, such as genomics, for building a wider knowledge base that individual drug makers could utlisie better to create drugs that take into account the more individual requirements of different populations.
Finally, Cornell commented on the potential in the future for using computational design and AI to develop drugs more safely, circumventing the need for animal models, and improving time from design to market.
Listen to the full episode here >>>
Related News
-
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Alzheimer’s drug Leqembi rejected by EU drug regulator
The European Medicine’s Agency (EMA), the drug regulator for the EU, rejected Eisai and Biogen’s Alzheimer’s drug product Leqembi, citing the drug’s slowing of cognitive decline did not outweigh the risk of serious brain swellin... -
News What can you expect from CPHI Milan 2024?
CPHI Milan 2024 marks the 35th anniversary of CPHI. The 35th Edition of the show, taking place 8–10 October, promises to be a celebration of everything pharma, covering every sector, and featuring thought leaders and trailblazers shaking up the i... -
News Second obesity drug candidate from Roche shows early trial success
Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics. -
News Tumour microproteins could provide basis for cancer vaccines
A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine. -
News Esteve invests €100 million in new manufacturing plant in Spain
Spain-headquartered CMO Esteve expands its manufacutring capacity in plants in Girona, Spain to increase global API offerings with advanced technological solutions, through a weighty investment of €100 million.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance